The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant - Top-Institutions - MDSpire

The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant

  • By

  • Saurabh Zanwar

  • Eapen K. Jacob

  • Carl Greiner

  • Kevin Pavelko

  • Michael Strausbauch

  • Emilie Anderson

  • Arini Arsana

  • Megan Weivoda

  • Mithun Vinod Shah

  • Taxiarchis Kourelis

  • September 26, 2023

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Immunology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Cancer Immunotherapy

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Genomic Medicine

  • #4

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Immunotherapy

Original Source(s)

The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant

  • by Saurabh Zanwar, Eapen K. Jacob, Carl Greiner, Kevin Pavelko, Michael Strausbauch, Emilie Anderson, Arini Arsana, Megan Weivoda, Mithun Vinod Shah, Taxiarchis Kourelis

  • September 26, 2023

Related Content

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min